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CHAPTER-I 
1. INTRODUCTION 
 
1.1. Diabetes Mellitus 
 
Diabetes mellitus is one of the most common and challenging disease 
conditions of 21
st
 century.  WHO defined Diabetes mellitus as a metabolic disorder of 
multiple etiologies characterized by chronic hyperglycemia with disturbance in 
carbohydrate, fat and protein metabolism resulting from defects in insulin, its action 
or both. It is a chronic complex progressive and multifactorial disorder with life 
threatening micro and macrovacular complications. It is a major cause of morbidity 
and mortality.  Prevalence of DM are about more than 150 million diabetics across the 
world and more than one fifth of them are Indians. International Diabetes Federation, 
India has been declared India as “Diabetic Capital of the World” at the recent 
Conference in Paris.
[26]
 
Diabetes mellitus is complex, heterogeneous and polygenic metabolic disease 
where there will be an absolute lack of insulin, decreased sensitivity to insulin or both 
and which results in abnormal glucose homeostasis and subsequent hyperglycemia.  
Mutual interaction between genetic and environmental factors plays an important role 
in the pathogenesis of diabetes mellitus. DM has been characterized by a variety of 
causes such as obesity, abdominal adiposity, genetic, ethnicity etc. 
1.2. BMI Related Diabetes Mellitus 
Obesity and increased BMI have a great impact on diabetes. The association 
between increased BMI and weight gain and risk of Diabetes mellitus is significant 
among Asians. Waist circumference (WC) cut point for Indians for any cardio- 
metabolic risk factors is 87 cm for men and 82 cm for women whereas that of BMI is 
23 kg/m2 in both sexes. It is found that the developing countries adopt the western life 
styles like decreased physical activity and over consumption of cheap, energy dense 
food for past 20 years and as a result the rate of obesity has tripled in developing 
countries. Such changes have a direct influence on the child health of the country; the 
prevalence of overweight ranges from 10 to 25%.
[35]
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1.3. Prevalence Of Diabetes Mellitus 
Diabetes mellitus has a strong genomic association, genome-wide association 
studies has catalogued a number of gene that have an influence on DM (with modest 
odds ratio ranges between 1.2 to 1.5) and they include TCF7L2, HHEX, CDKAL1, 
SLC30A8 etc. 
In India nearly 75% of the Type-II DM has first degree family history of 
diabetes indicating a strong familial aggregation.  Prevalence of insulin resistance is 
found to be high in Asian Indians and they need higher amount of insulin to maintain 
normoglycemia, Comparison of Asian Indians, Europeans and other ethic groups have 
shown that the former higher insulin response than others, at fasting and in response 
to glucose. Asian Indians also have some factors which decreases the insulin 
sensitivity such as central obesity and high percentage of body fat in comparison to 
many other populations.
[30]
 
The incidence of diabetes is growing rapidly both in the United States and 
worldwide. For example, it is estimated that more than 180 million peoples are 
affected with diabetes, and also prevalence will be expected to more than double by 
the year of 2030. In the United States, approximately 21 million peoples are estimated 
to suffer from diabetes, and it is also a major cause of morbidity and mortality. 
Diabetes is heterogeneous group of syndrome characterized by an elevation of blood 
glucose caused by a relative or absolute deficiency of insulin. The American Diabetes 
Association (ADA) recognizes four clinical classifications of diabetes: Type-I 
diabetes (formerly insulin-dependent diabetes mellitus), Type-II diabetes (formerly 
non-insulin dependent diabetes mellitus), gestational diabetes, and diabetes due to 
other causes (e.g., genetic defects or medication induced). Gestational diabetes is 
defined as carbohydrate intolerance with onset or first recognition during pregnancy. 
It is important to maintain adequate glucose control during pregnancy, because 
uncontrolled gestational diabetes can lead to fetal macrosomia (overly large body) and 
shoulder dystocia (difficult delivery), as well as neonatal hypoglycemia. 
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1.4. Types of Diabetes 
Based upon the etiology, diabetes mellitus can be divided into two main types 
Type- I- Insulin dependent diabetes mellitus (Juvenile DM) 
Type -II- Non- Insulin dependent diabetes mellitus(Adult type) 
Type –I- occurs in childhood, mainly due to destruction of pancreatic beta cell 
islets through auto-immune mediated, resulting in absolute insulin deficiency. 
Type –II  is associated with an adulthood and elderly people, which are mainly 
due to insulin resistance or abnormal insulin secretion.
[26]
 
1.4.1. Type-I- Diabetes Mellitus 
The disease is characterized by an absolute deficiency of insulin caused by 
massive β-cell necrosis or loss of β-cell function is usually ascribed to autoimmune-
mediated processes directed against β cell, and it may be triggered by an invasion of 
viruses or the action of chemical toxins which are involved destruction of β-cells, the 
pancreas fails to respond to glucose due to lipolysis, proteolysis, and glycogenolysis. 
Type 1 diabetes mellitus have shown classic symptoms like polydipsia, polyphagia, 
polyuria, and weight loss. The development and progression of neuropathy, 
nephropathy, and retinopathy are directly related to the extent of glycemic control 
(measured as blood levels of glucose and/or hemoglobin A1c [HbA1c]. Treatment 
purpose nowadays using required quantity of exogenous insulin administered 
subcutaneous route to avoid the catabolic state that results from and is characterized 
by hyperglycemia and life-threatening ketoacidosis. Amylin is a hormone that is co 
secreted with insulin from pancreatic β-cells following food intake. Pramlintide 
[PRAM-len-tide] a synthetic analog of amylin, may be used as an adjunct to insulin 
therapy. Other methods of insulin delivery, such as transdermal, buccal, and intranasal 
are currently under research progress. 
 
1.4.2. Type –II Diabetes Mellitus 
 
Type-II Diabetes Mellitus is multifactorial dysfunction of pancreatic β-cells 
due to influenced by genetic factors, ageing, obesity, and peripheral insulin resistance 
rather than by autoimmune processes or viruses. The goal for treating Type-I diabetes 
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mellitus is to maintain blood glucose concentrations within normal limits and to 
prevent the development of long-term complications of the disease. Weight reduction, 
exercise, and dietary modification decrease insulin resistance and correct the 
hyperglycemia of Type-II diabetes in some patients. However, most patients are 
dependent on pharmacologic intervention with oral hypoglycemic agents. As the 
disease progresses β- cell function declines, and insulin therapy is often required to 
achieve satisfactory serum glucose levels. 
 
1.5. Causes of Diabetes
41
 
Causes of diabetes depends on the type of diabetes. Type-I DM occurs mainly 
due to beta cell destruction, mediated through either immune mediated or idiopathic, 
whereas type-II diabetes occurs mainly due to insulin resistance or with relative 
insulin deficiency. Diabetes is also associated with life style factors and genetics. 
Other e are various types of other factors that involved in the development of diabetes 
which are the genetic material such as chromosomal and mitochondrial DNA 
mutation. Sometimes drugs and chemicals such as pentamidine, nicotic acid, 
glucocorticoids, thyroid hormones, beta adrenergic agonists,  thiazides, alpha 
interferon can cause diabetes mellitus.abnormalities in the pancreas such as 
pancreatitis,pancresctectomy, neoplasia, cystic fibrosis fibrocalculous pancreatopathy 
can develop diabetes. 
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Figure No:1: Pro-Insulin Biosynthesis 
 
 
 
 
 
1.6. Pathophysiology of Diabetes Mellitus
39
 
Diabetes mellitus has a profound adverse effect on quality of life in terms of 
social, psychological well-being as well as physical health. Diabetic complications are 
mainly mediated through oxidative stress such as increased production of Reactive 
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Oxygen Species (ROS) or impaired antioxidant defence system. Enhancement of 
lipidperoxidation, alteration in antioxidant enzymes and impaired glutathione 
metabolism are the main factors involved in the development of diabetes. Production 
of free radicals are involved in the pathogenesis of various type of disease including 
diabetes mellitus. Increased formation and accumulation of advanced glycation 
products elimination (AGEs) also involved in the diabetic complications, such as 
retinopathy, neuropathy, nephropathy and renal dysfunction through a series of 
pathological changes. The several hormones are involved in the regulation of blood 
glucose level, the most importat alteration between insulin and glucagon. When 
imbalanced occurs in the level of hormones in the body, sugar starts accumulating in 
the blood when concentration of glucose increased in the blood then finally it will 
passes in urine along with other minerals. In most cases of diabetes, T-cell mediated 
action based 90% of the pancreatic islet beta cell destruction and also serological 
markers such as islet cell secreting enzymes are glutamic acid decorboxylase (GAD) 
are involved in the beta cells destruction.  
1.7. Mucoadhesive Polymers Properties
3 
 
1. It must be loaded substantially by the active compound. 
2. Swell in the aqueous and acidic biological environment of the delivery–
absorption site. 
3. Interact with mucus or its components for adequate adhesion. 
4. Swelled, they allow controlled release of the active compound. 
5. Excreted unaltered or biologically degraded to inactive, non-toxic  oligomers. 
6. Sufficient quantities of hydrogen bondingwith each chemical groups. 
7. Possess high molecular weight. 
8. Selective polymer has high chain flexibility. 
9. It creates suface tension will induce penetration into mucous layer 
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1.8. Polymers In Mucosal Drug Delivery
7
 
 
Bioadhesive   polymeric   systems have   been used since long time in   the   
development   of products for various   biomedical   applications    which    include   
denture   adhesives   and    surgical glue.  After  a  lot   of   research,   the   researchers   
are   of   the  view   that  a   polymer   will  exhibit   sufficient   Mucoadhesive   
property   if   it   can   form   strong   intermolecular   hydrogen   bonding    with    the   
mucosal  layer,  penetration  of   the   polymer   into   the   mucus   network  or  tissue  
crevices,  easy   wetting   of   mucosal   layer   and  high   molecular    weight   of   the    
polymer   chain. Polymers used   in mucosal   delivery system may be   of   natural or 
synthetic origin.  In   this   section we will    briefly   discuss   some of    the    
common   classes    of    mucoadhesive    polymers.
 
 
1.8.1. Hydrophilic Polymers 
 
The   polymers  are  soluble  in   water.   Matrices   developed   with these   
polymers   swell   when   put   into   an   aqueous    media    with   subsequent    
dissolution  of   the   matrix
.[4]
  The   polyelectrolytes   extend  greater   mucoadhesive  
property    when   compared   with   neutral  polymers. Anionic polyelectrolytes,   Eg: 
poly (acrylic acid)   and    carboxy methyl   cellulose,  have   been   extensively   used    
for   designing   mucoadhesive  delivery systems   due   to  their   ability   to   exhibit   
strong    hydrogen    bonding   with   the    mucin present   in    the   mucosal   layer. 
Chitosan    provides    an   excellent    example  of cationic   polyelectrolyte,  which  
has  been   extensively  used   for   developing   mucoadhesive polymer   due  to  its   
good biocompatibility and biodegradable properties. Non-ionic 
polymers,Eg:poloxamer,  hydroxyl propyl methylcellulose,   methyl cellulose,  poly 
(vinyl alcohol)  and  poly  (vinyl pyrrolidone),have also been used for   mucoadhesive   
properties.  The   hydrophilic polymers form viscous solutions when   dissolved   in 
water   and   hence  may also be used  as viscosity modifying enhancing agents in the 
development of liquid ocular   delivery  systems  so   as   to  increase   the 
bioavailability   of   the   active  agents  by reducing the drainage of the  administered 
formulations. These polymers may be directly compressed  in the presence of drugs 
which are compressed form of mucoadhesive delivery  system. 
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1.8.2. Hydrogels 
 
Hydrogels  defined  as   three-dimensionally   crosslinked   polymer   chains 
which   have   the   ability   to   hold  water   within   its   porous   structure. The   
water   holding   capacity  of   the  hydrogels   is   mainly   due    to   the  presence   of   
hydrophilic functional  groups  like   hydroxyl,   amino   and   carboxyl  groups.  
Hydrogels    are   prepared by   the  condensation reaction of poly (acrylic acid)  and   
sucrose    indicated an  increase   in  the   mucoadhesive   property  due to cross 
linking density  and  was   attributed to  increase in the poly (acrylic acid) chain   
density per unitarea. Acrylates have been used to develop    Mucoadhesive delivery 
systems which has the ability to deliver   peptide   bioactive   agents   to   the   upper   
small  intestine    region   without   any   change   in   the   bioactivity  of  peptides.  In  
addition  to   the   drug targeting,   Mucoadhesive   hydrogel  based   formulations   for 
improving   the   bioavailability   of   the   poorly   water  soluble  drug. This   was   
attributed   to   the   increased   retention   time   of   the   delivery  system   within   
the  gastrointestinal  tract.
[5] 
 
1.8.3.  Thiolated Polymers 
The   presence   of   free   thiol   groups   in    the   polymeric    skeleton    
helps    in   the   formation   of    disulphide   bonds   with   that   of    the   cysteine-
rich   sub-domains   present in   mucin   which   can    substantially  improve    the   
mucoadhesive   properties   of    the    polymers (e.g. poly (acrylic acid) and chitosan)  
in   addition  to    the    paracellular    uptake    of    the    bioactive agents. 
 
1.8.4. Lectin-Based Polymers 
Lectins   are   proteins    which    have    the   ability  to   reversibly    
bind    with   specific   sugar/carbohydrate    residues   and   are   found   in   both   
animal   and   plant   kingdom    and various  microorganisms.  The   specific  affinity  
of   lectins   towards    sugar   or carbohydrate   residues   provides    them   with   
specific    cyto-adhesive    property   and  it is  being explored  to   develop   targeted   
delivery   systems.   Lectins    extracted   from   legumes   have   been widely   
explored   for   targeted  delivery   systems.   The   various    lectins   which    have   
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shown specific    binding   to   the   mucosa   include   lectins    extracted   from   Ulex 
europaeus ,  soybean, peanut   and   Lens culinarius. 
 
1.9. Mechanism of Mucoadhesion
 
Thus, the mechanism of mucoadhesion is generally divided in two steps, the 
contact stage and the consolidation stage (Figure 2). The first stage is characterized by 
the contact between the mucoadhesive and the mucous membrane, with spreading and 
swelling (step 1) of the formulation. Essentially, there are two theories explaining the 
consolidation step: the diffusion theory (step 2) and the dehydration theory(step 3). 
 
Figure. No: 2:  The two steps of the mucoadhesion process 
 
 
 
 
Step 1 :-The wetting and swelling step occurs when the polymer spreads over 
the surface of the biological substrate or mucosal membrane in order to develop an 
intimate contact with the substrate Bioadhesives are able to adhere to biological 
membrane or bond with biological tissues due to alteration of surface tension and 
forces that exist at the site of adsorption or contact. Swelling of polymers occur 
because the components within the polymers have an affinity for water.
[12] 
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Figure. No: 3: Wetting and Swelling of Polymer 
 
Step 2 : The surface of mucosal membranes are composed of high molecular 
weight polymers known as glycoproteins. In this step interdiffusion and 
interpenetration takes place between the chains of mucoadhesive polymers and the 
mucous gel network creating a great area of contact. The strength of these bond 
depends on the degree of penetration between the two polymer groups. In order to 
form strong adhesive bonds, one polymer group must be soluble in the other and both 
polymer types must be of similar chemical structure.  
 
 
Figure. No: 4: Wetting and Swelling of Polymer (Membrane) 
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Step 3:- In this step entanglement and formation of weak chemical bonds as 
well as secondary bonds between the polymer chains mucin molecule. The types of 
bonding formed between the chains include primary bonds such as covalent bonds, 
Van der waals interactions and hydrogen bonds. Both primary and secondary bonds 
are exploited in the manufacture of bioadhesive formulations which has strong 
adhesions between polymers are formed. 
 
     Figure. No: 5: Entanglement of Polymer and Mucus by Chemical bonds 
 
 
 
 
 
 
1.10. Advantages Of Mucoadhesives:
11
 
 
 A prolonged residence time at the site of drug action or absorption. 
 A localization of drug action of the delivery system at a given target site. 
 An increase in the drug concentration gradient due to the intense contact of 
particles with the mucosa. 
 Termination of therapy is easy (except gastrointestinal) 
   Permits localization of drug to the oral cavity for a prolonged period of time. 
 
1.11. Limitations 
 
 Drug administration via the buccal mucosa has certain limitations 
 Drugs, which irritate the oral mucosa, have a bitter or unpleasant taste, 
odour, cannot be administered by this route. 
 Only drugs with small dose requirements can be administered. 
 Only those drugs, which are absorbed by passive diffusion, can be 
administered  by this route. 
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 Over hydration may lead to the formation of slippery surface and structural 
integrity of the formulation may get disrupted by the swelling and 
hydration of the bioadhesive polymers. 
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CHAPTER-II 
2. LITERATURE REVIEW 
 
  Vishal Kadam,  et al, (2013)9 investigated development  and evaluation of 
Mucoadhesive buccal tablets containing antihypertensive drugs, Labetalol 
Hydrochloride. The tablets were prepared by direct compression method ,12 
formulations were developed using various concentrations of carbopol as primary 
polymer along with any of the secondary polymer viz HPMC,sodium alginate,xanthan 
gum,guargum. 
  Prasanth, et al, (2012)
10
 has formulated and evaluated the Mucoadhesive 
buccal patches of aceclofenac using different polymers like HPMC, Carbopol 
934,Polyvinyl alcohol, Poly  Vinyl Pyrolidine K30, Eudragit L100.Effect of variable 
polymers which significantly influenced Mucoadhesive characteristics and in vitro 
drug release using 3
2
 factorial design. 
Prasanna, et al, (2012)
23
 Formulated buccoadhesive films of glibenclamide 
buccal films by solvent casting technique by using different polymers such as HPMC 
15 cps, carbopol and polyvinyl pyrrolidine. The films were evaluated for 
physiochemical characteristics, in vitro drug release and ex vivo buccoadhesive 
strength. The satisfactory results were obtained in all prepared formulation and based 
the result G14 [PMC (150mg), CP (20mg) and PVP (30mg)] was the best one 
compared to others. The drug release of all formulations in buccal mucosa was 
studied which showed good correlation was observed between in vitro and in vivo co 
relation, thus revealing the ability of the formulation to reproduce the in vitro release 
pattern through  in vivo. 
Afrasim moin, et al, (2010)
 12
 has studied a sustained release matrix tablets of 
Diltiazem hydrochloride using Karaya gum (K), Locust bean gum (LB), Hydroxy 
propyl methyl cellulose (H) by direct compression. Hardness, friability, in-vitro 
release, drug content, SEM, FTIR, DSC has been evaluated. It concluded that Karaya 
gum combination with Locust bean gum (1:2) showed synergistic effect in controlling 
Diltiazem release. 
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Madgulkar, et al, (2009)
13
 has studied the development of buccal adhesive 
tablet with prolonged antifungal activity. The tablets were prepared by direct 
compression. carbopol 934P, hydroxypropylmethylcellulose K4M and poly vinyl 
pyrollidone were used as polymers. The tablets were evaluated for swelling index, 
mucoadhesive strength and in vitro drug release. The drug release and bioadhesion 
was dependent on type and relative amounts of the polymers. The release of the drug 
was slow and it prolonged miconazole action. 
Akapa, et al, (2008)
14
 has studied the patches containing Hydrochlorothiazide 
(HCTZ) formulated with Ethyl cellulose (EC) and Hydroxyl propyl metyl cellulose 
inter polymer complexes. Patches prepared by casting are evaluated for diameter, 
thickness, swelling behaviour buccoadhesive strength, drug content analysis and in-
vitro release studies. Higuchi’s analysis of the release mechanism indicated that the 
release of HCTZ from the patches formulated with 1:1 and 2:1 ratio’s of EC and 
HPMC predominantly occurred by a diffusional process. 
Emami, et al, (2008)
 15
 has studied a new buccoadhesive system for 
controlled release of  Verapamil hydrochloride developed  using Carbomer (CP), 
Hydroxy propyl methyl cellulose and Sodium carboxy metyl cellulose (NaCMC) by 
direct compression method. Thicknesses, weight variation, hardness, drug content 
uniformity, swelling, mucoadhesive strength, drug release are evaluated. The 
buccoadhesive containing 53% Cp and 13.3% HPMC showed suitable release 
kinetics. The release behavior was Non-Fickian controlled by a combination of 
diffusion and chain relaxation mechanisms and best fitted zero-order kinetics. 
Venkataraju, et al, (2007)
16
 have developed a controlled delivery system for 
Propranolol hydrochloride using the synergistic activity of Locust bean gum (LGB) 
and Xanthan gum (X) by wet granulation method. Prepared tablets were evaluated for 
hardness, friability, composition % and in-vitro release study. The XLBG formulation 
showed a required release rate with zero-order release kinetics due to the synergistic 
interaction of the two biopolymers that produced a strong and elastic gel in the 
presence of a ternary component control the drug release process. 
Sathya Meonah, et al, (2011)
48
 PharmacognosticalandHypoglycemic activity 
of different parts solanum nigrum linn palnt.The leaves and fruit of solanum nigrum 
have significant hypoglycaemic activity, the flavanoids present in the plant might be 
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an active components responsible for this activity. We progress on to isolate the active 
biocomponent responsible for the activity. 
 
Coman, et al, (2011)
46 
Plants and natural Compounds with Antidiabetic 
Action.Recently, more attention is being paid to the study of natural products as 
potential antidiabetics. This mini review of the current literature is structured into 
three main sections foucused on: (a) plant extracts, (b) plant biomolecules and (c) 
other molecules that have been used for their anitdiabetic effects. Potential molecular 
mechanisam of action are also discussed. 
Gupta, et al, (2007)
25
 Tetrabutylammoniumbromide mediated Knoevengel 
condensation in water: synthesis of cinnamic acids.A simple, mild and environment-
friendly procedure has been developed for Knoevenagel condensation between 
aromatic aldehydes or ketones and malonic acid in the presence of 
tetrabutylammoniumbromide and K2CO3 under microwave irradiation in water, The 
products areobtained in excellent yields and are in a state of high purity. 
Agrawal, et al, (2012)
28
 Reviewed on Thiozolidinone and considered it as a 
biologically important active scaffold that possesses almost all type of biological 
activities. Successful introduction of ralitoline as a potent anti-convulsant, etozoline 
as a anthihypertensive, piogliazone as a hypoglycemic agent and thiozolidomycin 
activity against streptomyces species proved potential of thiozolidinone moiety. This 
diversity in the biological response profile has attracted the attention of many 
researches to explore this skeleton to its multiple potential against severa; activities. 
This review is complementary to earlier reviews and aims to review the work reported 
on various biological activities of thiozolidinone derivatives from year 2000 to the 
beginning of 2011. Data are presented for active compounds, some of which have 
passed the preclinical testing stage. 
Ronan Roussed, et al, (2012)
27
 Use of TZD was not associated with increased 
incidence of major cardiovascular events in patients with diabetes from this large 
registry. Older patients experienced an increased risk of CHF over the study interval. 
Limitations of this study include its observational design and thus unmeasured 
confounders cannot be excluded. 
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Shih-Ann Chen, et al, (2012) Demonstrated that TZDs had obvious 
protective effects on the development of AF diabetic patients. Drugs acting as ligands 
to the PPAR-y may be potential up stream therapies fo AF prevention. 
Mueller, et al, (2012)
29
 Thiozolidiones decrease the proinflammatory 
cytokines IL-6 and IL-8 in endometrial stromal cells via PPAR-y-independent 
mechanism. A better understanding of the anti-inflammatory action of this class of 
drugs may improve their safety and efficacy for endometriosis treatment. 
Rosanna Maccari, et al, (2011)
30 
Evaluated2-Thioxo-4-thiazolidinone 
derivatives were as aldose reductase inhabitors (ARIs) and most of them exhibited 
good or excellent in vitro efficacy. Out of the tested compounds, most N-
unsubstituted analogues were found to posses inhibitory effects at low micromolar 
doses and two of them exhibited higher potency than sorbinil, used as a reference 
drug. 
Rosaria Ottana, et al, (2011)
31
 Explored a new set of suitably substituted 
compounds for more effective 5-arylidence-4-thiazolidinones as aldose reductase 
inhibitors, (4,5 and 8 ). Acetic acids 5, particularly 5a and 5h, proved to be interesting 
inhibitors of the enzyme as well as excellent antioxidant agents that are potentially 
able to counteract the oxidative stress associated with both diabetic complications as 
well as other pathologies. Molecular docking experiments supported SAR studies. 
Changyou Zhou, et al, (2010)
45
 Performed Systematic structure-activity 
relationship (SAR) studies of ascreening lead led to the discovery of series of 
thiozolidinediones (TZDs) as potent GPR40 agonists. Among them, compound C 
demonstrated an acute mechanism-based glucose-lowering in an intraperitoneal 
glucose tolerance test (IPGTT) in lean mice, while no effects were observed in 
GPR40 knock-out mice. 
Ossama EI-Kabbani, et al, (2010)
41
 Determined the structure of aldehyde 
reductase (ALRI) internary complex with the concenzyme NADPH and [ 5-(3- 
carboxymethoxylidene)-2, 4-dioxothiazolidin-3 yl] acetic acid (CMD), a potent 
inhibitor of aldose reducaste (ALR2), at 1.99 A resolution. Molecular modeling 
calculations and inhibitory activity measurements of CMD and and [ 5-(3- 
hydroxybenzylidene)-2, 4-dioxothiazolidin-3 yl] acetic acid (HMD) indicated that 
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stacking interactions with several conserved active site tryptophan residues and 
hydrogen-bonding interactions with none-conserved C- terminal residue Leu 300 in 
ALR2 (Pro301 in ALR1) contributed to inhibitor selectivity. 
Nanjan, et al, (2010)
36
 Designed somenovel glitazones based on the structure-
activity relationships as possible PPAR-y agonists. The manually designed glitazones 
were synthesized by using the appropriate synthetic schemes and screened for their in 
vitro antihyperglycemic activity by estimating glucose uptake by rat hemi-diaphragm, 
both in the absence and in the presence of external insulin. Some of the gliazones 
exhibited good antihyperglycemic activity in presence of insulin. 
Rosaria Ottana et al, (2009)
43
 Identified effective low molecular weight 
ononphoshorus monoanionic inhibitors of PTPs and synthesized 4-[ 5-arylidene -4-
oxo-2-phenyliminothiazolidin-3yl)methy1]- benzoic acids (4)  and evaluated their 
inhibitory activity against human PTP1B and LMW-PTP enzymes. The introduction 
of a a-phenylimino moiety onto the 4-thiazolidinone ring was designed to enhance the 
inhibitor/enzyme affinity by means of further favourable interactions with residues of 
the active site and surrounding loops. Molecular modeling experiments inside the 
binding sites of  both enzymes were performed. 
Guorong Fana, et al, (2009)
34 
Evaluate toxicity and toxicokinetics of MCC-
555, a treatment candidate for type 2 diabetes, a novel thiazolidinedione which has 
comparatively high anti-diabetic efficacy in beagle dogs. During the treatment and 
recovery periods, the effects of the test agent on mortality, body weight, food 
consumption. Hematology, serum biochemistry urinalysis, electrocardiogram (ECG), 
organ weights, bone marrow and histopathology were examined. Metabolites and 
metabolic style of MCC-555 are to be approved. 
Kim Henriksen, et al, (2009)
37
 Performed a head-to-head comparison of 
equipotent glucose lowering concentrations of the partial PPARy agonist 
balaglitazone and the full agonist piog;itazone in male diet-induced obese rats, to 
investige effects on bone formation, fluid retention and fat accumulation. MR scans of 
body fat and water showed that all treatment groups increased their fat mass, whereas 
only the pioglitazone 30 group accumulated water. Pioglitazone treatment led to 
reduction of the bone formation marker osteocalcin, whereas balaglitazone treatment 
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did not affect it. Balaglitazone is a novel PAPRy agonist, which potently lowers 
glucose levels, while it neither affects fluid retention nor bone formation parameters. 
Sriman Narayanan, et al, (2009)
39
 Synthesized a series of novel 
dispiropyrrolidines by 1,3 dipolar cycloaddition reaction with 5-arylidene-1,3-
thiazolidine-2,4-dione and 5-arylidence-4thioxo-1,3-thiazolidine-2-one derivatives as 
dipolarphiles. The Structure and stereochemistry of the cycloadduct have been 
established by single crystal X-ray structure and spectroscopic techniques. Molecular 
docking studies were performed on 1FM9 protein. The synthesized compounds were 
screened for their antidiabetic activity. 
Klopper, et al, (2009)
41
,Concluded that A375 (DRO) melanoma cell growth 
is inhibited by rexinoid and TZD treatment and this response id dependent on RXR 
and PPARy receptor expression. M14 (5-16) melanoma cell growth is inhibited by 
rexinoid and retinoid treatment, and this response is dependent on RXR expression. 
These findings may help guide molecular-based treatment strategies in melanoma and 
provide insight for mechanisms of resistance to nuclear receptor targeted therapies in 
certain cancers. 
Venero, et al, (2008)
38
 Recognized paradoxical respose of HDL-C to some 
PPAR ligands and suggest that clinicians be aware that resiglitazone with fenofibrate 
may reduce HDL-C level and consider alternative medications should a decrease in 
HDL-C occur. 
Giuseppe Derosa, et al, (2008)
42
,Observed No Change BMI, probably 
because rosiglitazone was added to metformin, that could mitigate the body increase 
of rosiglitazone. Rosiglitazone improved glycemic control and insulin resistance 
correlated parameters when added to intolerant metformin patients. These data 
suggest that rosiglitazone may be the drug of choice for the treatment of overweight 
and obese type 2 diabetic patients. 
Marcin baranowski, et al, (2008)
31
 Investigated the effects of two-week 
pioglitazone treatment (3 mg/kg/d) on lipid and carbohydrate metabolism in the heart 
of rats fed on a standard chow or on a high fat diet (HFD) for three weeks. High-fat 
feeding increased myocardial protein expression of all peroxisome 
proliferatoractivated receptor (PPAR) isoforms. The greatest response was, however, 
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noted in the case of PPARy. Surprisingly, administration of pioglitazone induced 
accumulation of free fatty acids (FFA) and diacylglycerol in the heart in both groups, 
despite concomitant reduction in plasma FFA concentration. Result suggest that 
thiazolidinediones improve cardic insulin sensitivity by mechanisms other than 
reduction in intramyocardial lipid content. 
Rosanna Maccari, et al, (2008)
30
 Reported a series of non-carboxylic acid 
containing 2,4-thiazolidinedione derivatives, analogues of previously synthesized 
carboxylic acids which we had found to be very active in vitro aldose reductase 
(ALR2) inhibitors. Although the replacement of the carboxylic group with the 
carboxamide or N-hydroxycarboxamide one decreased the in vitro ALR2 inhibitory 
effect, this led to the identification of mainly non-ionized derivatives with micromolar 
ALR2 affinity. The 5-arylidene moiety deeply influenced the activity of these 2, 4-
thiazolidinediones. 
Carroll et al, (2008)
41
 Identified a novel protein, mitoNEET, which was later 
shown to regulate the oxidative capacity of the mitochondria. This identified an 
alternative target for the glitazones suggesting a possible new drug target for the 
treatment of neurodegenerative diseases. Molecular docking studies employing the 
reported crystal structure revealed five possible binding pockets on mitoNEET. 
Alvarex, et al,(2008)
38
 Demonstrated that a sunset of patients with T2DM 
experienced a paradoxic decrease in HDL-C when taking a fibrate TZD combination. 
Dundar et al, (2008)
37
 Prepared a series of flavonyl-2,4-thiazolidinediones by 
Knoevenagel reaction. The synthesized compounds were tested for their ability to 
inhibit rat kidney aldose reductase (AR) and for their insulinotropic activities in INS-1 
cells. 
Paola Vicini, et al, (2008)
41
 Synthesized 2-Heteroarylimino-5-benzylidene-4-
thiazolidinones, un-substituted or carrying hydroxyl,methoxy, nitro and chloro groups 
on the benezene ring and assyed in vitro for their antimicrobial activity against Gram 
positive and Gram negative bacteria, yeasts and mould.relationship of 33 analogues 
possessing the 2 heteroarylimino-4 thiazolidinone structure is analysed through 
QSAR models. 
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Oya Bozdag-Dundar, et al, (2008)
42
 Prepared a new series of chromonyl-2, 
4-thiazolidinediones by Knoevenagel reaction with substituted 3-formylchromones 
and unsubstituted (1) or substituted 2,4-thiazolidione (2). The synthesized compounds 
were tested for their ability to inhibit rat kidney AR by an in vitro spectrophotometric 
assay. 
Subho mozumdar, et al, (2008)
40
 Described a simple, efficient, 
stereoselective, one pot three component condensation reaction between thiazolidine-
2,4-dione, aldehyde and amine derivatives using monodispersed, recyclable and 
inexpensive Cu nanoparticles for the synthesis of thiazolidine-2,4-dione derivantives 
in excellent yields and high purity. 
Maccari, et al, (2006)
44
 Synthesized and tested several 5-benzyl-2,4-
thiazolidinediones (5-7) as in vitro aldose reductase (ALR2) inhibitors. Most of them, 
particularly N-unsubstituted 5-benzyl-2, 4dioxthiazolidin-3-yl) acetic acids 7, 
displayed moderate to high inhibitory activity levels. I(n detail, the insertion of an 
acetic chain on N-3 significantly enhanced ALR2 inhibitory potency, leading to acids 
7 which proved to be the most effective among the tested compounds. 
Aurelio Ortiza et al.,(2005)
45
,Carried out a novel reaction between 
oxazolidinethione and bromoacetyl bromide to afford N-substituted 2,4-
thiazolidinediones through an intramolecular nucleophilic substitution reaction. 
Maharana,  et al,(2012)
46
 Assessment of anti hyperglycaemic and antioxidant 
potential of leaves of Solanum nigrum linn.in alloxan induced diabetes.The present 
study report clearly depicated that the Solanum nigrum extract endowed with 
hypoglycaemic and anti hyperglycaemic activity due to its possible action on 
pancreatic and  extra pancreatic site of glucose and lipid metabolism as evidenced by 
insulinotropic and antioxidant properties of the extract. 
 
 
 
 
Department of Pharmacology Page 25 
 
CHAPTER-III 
3. AIM & OBJECTIVE 
 
 
Diabetes mellitus is a type of multifactorial disease due to less physical 
activity, improper food intake, hereditary and usage of drugs. Synthetic drugs can’t 
completely cure the diabetes mellitus but it can mitigate the symptoms and also it can 
possess few adverse effects such as hypoglycemia, liver toxicity, kidney toxicity, 
neuropathy, retinopathy, and immunological disturbances. Based on the above 
reasons, we have undertaken to investigate the synthetic origin of thiozolidione 
derivative as synthesized and modified with the help of knoevenagel condensation 
reaction and evaluated by using invivo techniques such as hypoglycemic effects in rat 
sand Oral Glucose Tolerance Test in rats. Based on the results to prepare 
mucoadhesive patch attached with thiozolidine dione derivatives evaluated by using 
specific invivo animal model  
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CHAPTER-IV 
4. PLAN OF WORK 
 
 
 
1. Review of literatures 
2. Synthesis of  modified Thiozolidine dione 
3. Invivo Antidiabetic study of modified thiozolidine dione 
 Normal animal 
 OGTT 
 Hypoglycemic effect 
4. Formulation of mucoadhesive Thiozolidine dione tablets 
 Powder characteristics 
 Preparation of mucoadhesive tablets by direct compression 
5. Physiochemical Evaluation 
6. Streptozotocin induced diabetic study 
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CHAPTER-V 
5. MATERIALS AND METHODS 
 
 
 
   List of Chemicals Used: 
 
S. No 
 
Chemicals 
 
Company 
1. Aceclofenac Micro labs 
2. Xanthan gum Merck 
3. HPMC  Merck 
4. Guar gum Merck 
5. Lactose  SD Fine chemicals 
6. Magnesium stearate SD Fine chemicals 
 
 List of Equipment Used: 
 
S. No Equipments / Instrument Company 
1. Digital balance Shimadzu 
2. Digital pH meter Mettler Toledo 
3. Hardness tester Monsanto hardness tester 
4. Dissolution apparatus Lab India 
5. U.V.Spectrophotometer Shimadzu 
6. Bulk density apparatus Mahalakshmi scientific 
7. Tablet Punching machine Sakthi Multistation tablet press 
8. FTIR Perkin Elmer 
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5.1. Synthesis of the Compound 
 
 In a 500-cc round-bound flask g(0.5mole) of O- Phenylenediamine is treated 
with 32 cc. (34.6g.) of 90 percent formic acid (0.75mole). The mixture is heated in a 
water bath at 100
o
C for two hours. After cooling, 10 percent sodium hydroxide 
solution is added slowly, with through mixing by rotation of the flask, until the 
mixture is just alkaline to litmus. The crude benzimadazole is collected with suction 
in a 75-mm. Buchner funnel used for filtration under ice-cold water and to rinse all 
solid out of the reaction flask. The crude product is pressed thoroughly on the filter, 
washed with about 50 cc, of cold water, and then purified without previous drying. 
 
 
 
 
 
5.2.  Reaction between 2,4 thiozolidine and 4,formyl benzimidazole 
 
Valizadeh et al, has reported the reaction between aldehyde and 2 methyl 
group of thiolidinedione using NH4CL and water under MW irradiation but the 
products obtained are αβ-unsaturated melonic acid i.e. reaction stops before 
decarboxylation. Our developed method involves the irradiation of a mixture aromatic 
aldehyde or ketone with 2 methyl group using TBAB(Tetra Butyl Ammonium 
Bromide), K2CO3 and water. As soon as irradiation s stopped after few minutes of 
followed by acidification with dil.Hcl and separated out which are of high purity. 
When a mixture of benzaldehyde (5mmol), thiozolidinedione (5mmol), TBAB 
(2.5mmol), K2CO3(2.5mmol) and distilled water (10mL)was heated under 
microwaves for 5minutes at 900W, product was isolated as a pure product (TLC) in 
85% yield. 
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Pharmacological Evaluation: 
5.3. Animals  
 Wistar rats (150 – 250 g ) used for the study were obtained from the animal 
house of the Department of Pharmacology, Karpagam College of Pharmacy, 
Coimbatore, Tamil Nadu. The animals are randomly selected, marked to permit 
individual identification and kept in their cages for at least 5 days prior to dosing to 
allow for acclimatization to the laboratory conditions. The animals were housed 6 per 
cage in a polypropylene food and water ad libitum.
18
 All animal experiments were 
conducted in compliance with (Organization for Economic Cooperation and 
Development) OECD Guideline and approved by the Institutional Animal Ethics 
Committee, Karpagam University. 
 
 
 
Department of Pharmacology Page 30 
 
5.3.3. Drug administration 
 Animals are fasted prior to dosing (food but not water should be withheld for 
overnight). After that animals are weighed and the test substance administered. The 
healthy rats has been taken and divided into 4 different groups. The test substance was 
administered in a single dose by oral gavages, using a curved and ball tipped stainless 
steel feeding needle. 
 
 
5.3.4. Experimental Design 
 In this study, 4 groups of 6 rats each were given with 5, 50 and 300 and 2000 
mg/kg of the extract (p.o.) After drug administration the food is withheld for 3 hours. 
The animals are observed continuously for the first 2 hours, then occasionally up to 6 
hours and then daily up to 14 days, post treatment to observe for any symptoms of 
toxicity and morality were carried out and changes were noted (OECD, 2001). 
 
5.3.5. Clinical Observation 
 All animals were monitored continuously with special attention for 4 hr after 
dosing for signs of toxicity. Additional observations are also done for the next 14 days 
for any other behavioural or clinical signs of toxicity. Weight changes are calculated. 
At the end of the test animals are weighed. LD50 values are established using the 
formula. 
Dose Calculation Equation 
LD50 = higher dose - (a X b)/n 
Where, 
     a = dose difference 
     b= animal died 
     n= No. of animals in each group 
    ED50=LD50 
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5.3.6. Selection of Test animals 
 Male wistar rats weighing 150 -200g were used for the present work. The 
animals used for the experiment were maintained under standard laboratory 
conditions in an animal house of  Karpagam College of Pharmacy approved by the 
committee for the purpose of control and supervision on experiments on animals 
(IAECNO. KU/IAEC/ M. Pharm/169) under 12 h dark/light cycle and controlled 
temperature 24±2C. They had free access to food and water ad libitum. The animals 
were acclimatized to the laboratory for a period of 7 days, before the commencement 
of experiment. 
5.3.7. Induction of Diabetes in Experimental Animals 
 Experimental diabetes was induced by single intra-peritonial injection of 25 
mg/kg of streptozotocin (STZ), freshly dissolved in cold citrate buffer (pH 4.5) after 
15 min of intra-peritonialinjection of nicotinamide (110 mg/kg) prepared in normal 
saline. Rats with marked glycosuria (Fasting blood glucose level greater than 200 
mg/dL) after one week of administration of STZ were used for the study. 
5.3.8. Assessment of diabetes 
 Diabetes was confirmed after 48 hr of streptozocin injection, the blood 
samples were collected through tail vein and plasma glucose levels were estimated by 
glucose oxidase method (accu check active glucometer). The rats having fasting 
plasma glucose levels more than 200 mg/dL were selected and used for the present 
study. 
5.4. Oral Glucose Tolerance Test 
The Oral Glucose Tolerance test (OGTT) measures the body’s ability to use 
glucose, which is the body’s main source of energy. Oral glucose tolerance test was 
performed in overnight fasted (18 hours) normal rats. Oral glucose tolerance test 
(OGTT) results have been expressed on table below. Half hour after the glucose 
treatment, all the groups of animal blood glucose levels were significantly increased. 
The blood glucose levels were significantly decreased when compared to control and 
positive control at 1hr and each and every ½ hour blood glucose levels were changes 
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in the dose dependent manner extract treated group of animals compared to control 
and positive control but 2mg/kg produce the equipotent activity. 
 
5.5.  Excipient Profile 
5.3.1. Hydroxy Propyl Methyl Cellulose (HPMC)
18
 
Synonyms : Benecel MPHC, Cellulose hydroxyl propyl  
methyl ether, E646, HPMC, Methocel, Metholose, 
Methyl cellulose propylene glycol ether, Methyl 
hydroxyl propyl cellulose, Pharmacoat. 
 
Chemical name : Cellulose, 2-Hydroxy propyl methyl ether. 
Empirical 
Formula  : O-methylated & O- (2-hydroxy propylated  
cellulose) 
 
Description : Odourless, tasteless, white or creamy white  
colored fibrous or      granular. 
 
Density  :  0.341 g/cm
3
 
Solubility :  Soluble  in cold water, forming a viscous  
colloidal solution, practically  insoluble  in  
chloroform, ethanol  and  ether. 
 
Functional  
Category : Coating agent, film former, rate controlling  
polymer for sustained release, stabilizing agent,  
suspending agent, tablet binder, viscosity increasing 
agent.. 
 
Storage : Should  be  stored  in  well  closes  container  in  
a cool, dry place. 
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5.3.2. Magnesium Stearate 
 Synonyms  : Magnesium octadecanoate, Stearic acid  
magnesium salt, Octadecanoate acid,  
magnesium salt. 
 
Chemical name : Octadecanoic acid magnesium salt 
Empirical formula & 
Molecular Wt    : C36H70MgO4, 591.34 
 
Structural 
formula  : [CH3 (CH2)16COO] 2 Mg 
 
Density  : 0.159 g/cm
3
 
Solubility : Practically insoluble in ethanol, ether and water,  
slightly soluble in warm benzene. 
Functional  
Category  : Tablets and Capsule lubricant. 
 
Storage : Should be stored in well closed container in a  
cool, dry place. 
5.3.3. Guar Gum 
Synonyms  : Guar gum, Jaguar gum 
Chemical name : Galactomannan polysaccharide 
Empirical formula 
Molecular Wt   :   (C6H12O6)n ,  220000 
 
Structural  
Formula  : It has linear chain of (1-4)-B-D-mannopyranosyl units    
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with d-galactopyranosyl units  
Solubility : Practically insoluble in ethanol, ether and water,  
slightly soluble in warm benzene. 
 
Functional 
Category : Suspending agents, Tablet binders, Tablet  
disintegrant, Viscosity increasing agents. 
 
Storage  : Should be stored in well closed container in a  
cool, dry place. 
 
 
5.3.4. Xanthan  Gum
18
 
Synonyms  : Corn sugar  gum, Rhodigel 
Chemical name : Xanthan gum 
Empirical formula &  
Molecular Wt :  Dominant hexose units along with D-glucoronic  
   acid,2x10
6 
 
Structural  
Formula  : 5 Sugar residues: 2 glucose, 2 mannose and 1  
glucoronic acid 
  
Solubility : Practically insoluble in ethanol, ether and water,  
slightly soluble in warm benzene. 
Functional  
Category : Stabilizing agents,Suspending agents, Viscosity  
increasing agents. 
 
Storage  : Should be stored in well closed container in a  
cool, dry place. 
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5.3.5. Lactose 
18
 
Synonyms : 4(β-D-galactosido)-D-glucose,  
Lactochem, Microtose, Milk sugar, Pharmatose,  
Saccharum lactis, Tablettose, zeparox. 
Chemical 
Name   :   O–β-D-Galactopyranosyl-(1     4)-α-D- 
glucopyranose anhydrous 
 
 O–β-D-Galactopyranosyl-(1     4)-α- 
 D-glucopyranose monohydrate 
 
Empirical formula &  
Molecular Wt : C12H22O11 - 342.3(anhydrous),C12H22O11.H2O – 
360.31(monohydrate) 
 
Description : White to off white crystalline particles or  
powder, odorless, slightly  sweet – tasting 
 
Density  :  1.552 g/cm
3 
 
Hygroscopicity : It is stable in air and is unaffected by humidity  
at room temperature. 
 
Solubility : Practically insoluble in chloroform, ethanol,  
ether, and slightly    soluble in water 
 
Functional category  : Tablet and capsule diluents 
Storage    : Should be stored in well closed container in a  
cool, dry place. 
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5.6. Preparation of Mucoadhesive Tablets 
The mucoadhesive drug/polymer mixture was prepared by homogeneously 
mixing the drug with Xanthan gum, HPMC, Guar gum, Lactose, Magnesium stearate. 
The mixture of 150mg was then compressed using 6 mm diameter die in a 
single stroke multistation tablet machine. 
 
 Weighed all the ingredients and mixed thoroughly. Allow the mixture to pass 
thorough sieve no 60 & 80. Then added q.s isopropyl alcohol, make cohesive mass 
and passed through sieves no 20. Later dried the granules and separated through sieve 
no:35. 
 
5.7. Evaluation of Mucoadhesive Tablets  
The prepared mucoadhesive tablets were evaluated for following parameters. 
 
5.7.1. Weight uniformity & Thickness
  
 Initially individual weight of the tablets was calculated. The average weight of 
the formulated tablets was determined using electronic balance. Not more than two 
tablets should deviate from average weight.  
Weight variation = Initial wt – Average wt / Initial wt x 100 
Thickness was measured using screw gauge at different positions and average 
was calculated. 
5.7.2. Hardness  
 The hardness of the tablets of each batch was measured by hardness tester . 
The hardness was measured in terms of Kg/cm
2
 and it is found that hardness value of 
the formulation is 4. 
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5.8. Evaluation of Mucoadhesive characteristics 
a)  In-vitro mucoadhesive strength
21
 
The adhesive strength of the mucoadhesive tablets was measured on the 
“Modified Physical Balance Method”. The sheep buccal membrane was used as the 
model mucosal membrane. The fresh sheep buccal mucosa was cut into pieces and 
washed with phosphate buffer pH 6.8. A piece of mucosa was tied in to glass slide 
which was moistened with phosphate buffer pH 6.8. The tablet was stuck to the lower 
side of another glass slide with adhesive. The both pans were balanced by adding an 
appropriate weight on the left hand pan. The glass slide with mucosa was placed with 
appropriate support, so that the tablet touches the mucosa. Previously weighed beaker 
was placed on the right hand pan and water (equivalent to weight) was added slowly 
to it until the tablet detach from the mucosal surface. The weight required to detach 
the tablet from the mucosal surface gave the adhesive strength. The experiment was 
performed in triplicate and average value was calculated. 
 
 
Figure. No: 5: Mucoadhesive strength measurement device 
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b)  Ex-vivo residence time
21
 
 The ex-vivo mucoadhesion time was studied after application of tablets on 
freshly cut sheep buccal mucosa. The fresh sheep buccal mucosa was tied on the glass 
slide; the mucoadhesive core side of tablet was wetted with 1 drop of phosphate 
buffer pH 6.8 and pasted to the sheep buccal mucosa by applying light force with a 
finger tip for 30 seconds. The glass slide was then put in the beaker containing 100ml 
of the phosphate buffer pH 6.8 maintained at 37
o
C ± 0.2
o
C and stirring was applied 
slowly to stimulate the buccal cavity environment and it was supplied with aeration. 
The tablet adhesion was monitored for 7hrs. The time at which the tablet detaches 
from the sheep buccal mucosa was recorded as the mucoadhesion time. 
Figure. No: 7: Measurement of ex-vivo residence time 
 
 
  
c)  Swelling index  
 The swelling properties of the tablets were evaluated by determination of % 
swelling. The tablets of each formulation were weighed individually (W1) and placed 
separately in petri-dishes containing 2% agar gel. At regular time intervals 
(30,1,2,3,4,5,6 hours) the tablets were removed from petri-dishes and wiped off to 
remove the excess of water by using filter paper and the swollen tablets were 
reweighed (W2). 
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                          % Swelling index = [(W2 – W1) / W1] x 100 
d)  In-vitro release  
 The drug release rate from mucoadhesive tablets was studied using the USP 
XXIII (type II) rotating paddle method dissolution test apparatus. The dissolution test 
was performed using 500 ml of phosphate buffer pH 6.8 at 37±0.5
o
C with a rotation 
speed of 50 rpm. 
The samples (5ml, at each time) were withdrawn at pre-determined time 
intervals (0.5,1.0,2.0,3.0,4.0,5.0,6.0hr) from a zone midway between the surface of 
dissolution medium and the top of rotation paddle not less than 1cm apart from the 
vessel wall and volumes were replaced with fresh medium in order to maintain the 
sink condition. The samples were filtered through whatman’s filter paper and were 
analyzed by UV Spectrophotometry at 216nm against the phosphate buffer pH 6.8 as 
blank. The experiments for different formulations (F1-F6) were conducted in 
triplicate and average values were recorded. 
e)  In-vitro mucoadhesive permeation studies 
 The in-vitro Mucoadhesive drug permeation study of modified thiozolidine 
dione through the sheep buccal mucosa was performed using conventional permeation 
apparatus. The fresh buccal mucosa was tied to one end of open ended cylinder made 
up of glass, which acted as a donor compartment and the mucoadhesive tablets was 
placed with the core facing the mucosa. The donor compartment was filled with 10ml 
of phosphate buffer pH 6.8. The complete setup was then dipped into the receptor 
compartment containing phosphate buffer pH 6.8 which was maintained at 37
o
C ±0.2
o 
C and hydrodynamics in the receptor compartment was maintained by stirring with a 
magnetic bead at a constant speed. The 5ml of samples were withdrawn at 
predetermined time intervals (0.5,1,2,3,4,5,6 &7 hours) filtered through a 0.2-µ filter 
and then the amount of Aceclofenac released was estimated by measuring the 
absorbance at 216nm using UV spectrophotometer. The phosphate buffer pH 6.8 of 
same volume (5ml) pre warmed at 37
o
C ± 0.2
o
C was replaced to maintain its constant 
volume & sink condition. The cumulative amount of drug release was calculated and 
used while plotting the release and the release kinetics curves. 
 
Department of Pharmacology Page 40 
 
5.9. Streptozotocin Induced Diabetic Analysis 
 
Streptozotocin or Streptozocin or lzostazin or zanosar (STZ) is a synthetic 
glucopyranose derivative isolated by the fermentations of Streptomyces 
achromogenes which posses anti-tumor antibiotic activity. It can be used to induce 
both type 1 and type 2 diabetes. Chemically it is (2-deoxy–2(3-methyl-3-
nitrosoureido)-D-glucopyranose). The frequently used single i.v dose in adult rats to 
induce IDDM by immune system activation was found to be in between 40 and 
60mg/kg. NIDDM can also be induced in rats by intravenous or intraperitoneal 
treatment with 100mg/kg b.w. STZ on the day of birth.
[49]
 
 STZ decrease insulin biosynthesis and secretion by impairing glucose 
oxidation. STZ at first abolished the B cell response to glucose.  Temporary return of 
responsiveness than appears which is followed by its permanent loss and cells are 
damaged. STZ is taken up by pancreatic B cells via glucose transporter mainly 
GLUT-2. Intracellular action of STZ causes in changes of DNA I pancreatic B cells 
compromising its fragmentation. Alkylation of DNA is the main reason for the STZ 
induced B cells death. 
 STZ inhibits the Krebs cycle and decreases oxygen consumption by 
mitochondria and strongly limit mitochondrial ATP production and cause depletion of 
this nucleotide in B cells. Augmented ATP dephosphorylation increases the supply of 
substrate for xanthine and enhances for uric the final product of ATP degradation. 
 STZ is a Nitric oxide (NO) donor and NO was found to bring about the 
destruction of pancreatic islet cells. Hence it produces DNA damage. STZ is however 
not a spontaneous nitric oxide donor.  STZ was found to generate reactive oxygen 
species, which also contribute to DNA fragmentation. The formation of superoxide 
anions result from both STZ action on mitochondria and increased activity of xanthine 
oxidase. 
 STZ induced DNA damage activates poly ADP ribosylation leading to the 
depletion of cellular NAD+  and ATP content and thereby inhabition of  insulin 
biosynthesis and secretion. Calcium, which may also induce necrosis, does not seen to 
play a significant role. 
 
Department of Pharmacology Page 41 
 
 
CHAPTER-VI 
6. RESULTS AND DISCUSSION 
 
 
6.1. Synthesis of thiozolidine dione 
 
 
Theoretical  yield   =  Molecular weight of product / Molecular weight of  
reactant  × weight taken 
= (560/222×1.15)  
Theoretical  yield is found to be 2.90g 
Practical yield = 2.60g 
% yield = Practical yield / Theoretical  yield × 100 
% yield is found to be 89.65%w/w 
 
6.2.  Hypoglycaemic Activity 
The Hypoglycaemic activity test results indicates modified thiozolidine dione treated 
animals 2mg/kg, significantly has decreased blood glucose level when compared to 
control and positive control which are clarified in the Table No:1 
 
Table. No: 1 : Hypoglycaemic Activity 
 
Treatment Dose 
mg/kg 
0 min 0.5hr 1hr 
Control- Carboxy 
Methyl Cellulose (CMC) 
0.5% 68.00±2.429 68.17±2.587 71.83±2.372 
Positive Control 
(Pioglitazone)  
2 68.00±0.632 52.83±4.037** 32.83±1.515*** 
Formulated Drug 2 68.80±2.429 53.00±2.309** 34.17±1.138*** 
The glucose levels were analysed by using glucometer and each value is the mean 
±standard value (n=each group consist of 6 
animals)(P<0.05)*,(P<0.001)**&(P<0.0001)*** as compared to control & positive 
group evaluated by one way, ANOVA followed by Dunnet ‘t’ test. 
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Figure. No: 8: Hypoglycaemic Activity at 30mins 
 
 
 
 
 
 
Figure. No: 9: Hypoglycaemic Activity at 1 hour 
 
 
 
 
 
6.3. Oral Glucose Tolerance Test 
Oral glucose tolerance test (OGTT) results have been expressed on table below. 
Half hour after the glucose treatment, all the groups of animal blood glucose levels 
were significantly increased. The blood glucose levels were significantly decreased 
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when compared to control and positive control at 1hr and each and every ½ hour 
blood glucose levels were changes in the formulation treated group of animals 
compared to control and positive control but 2mg/kg produce the equipotent  anti 
diabetic action. 
Table. No: 2: Oral Glucose Tolerance Test 
 
 
Treatment Dose 
mg/kg 
0 min 0.5hr 1hr 
Control- Carboxy Methyl 
Cellulose (CMC) 
0.5% 68.00±2.429 142.5±6.292 187.5±9.465 
Positive Control 
(Pioglitazone) 
2 69.00±0.6325 104.2±7.323** 110.5±6.980*** 
Formulated Drug 2 68.80±2.245 128.3±6.009 147.3±2.404* 
 
The glucose levels were analysed by using glucometer and each value is expressed as 
Means ± SEM (n=6) )(P<0.05)*,(P<0.001)**&(P<0.0001)*** evaluated by one way, 
ANOVA followed by Dunnet ‘t’ test. 
 
Figure. No: 10: Oral Glucose Tolerance Test at 30 mins 
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Figure. No: 11: Oral Glucose Tolerance Test at 1Hour 
 
 
 
 
 
 
 
6.4. Evaluation of Mucoadhesive Tablets 
 
Table. No: 3: Evaluation of Mucoadhesive Tablets 
 
 
 
S.No. 
 
Formulations 
Evaluations 
Weight 
Variation % 
Thickness (mm) Hardness 
(Kg/Cm
2
) 
1. F1 2.0±0.3 2.4±0.05 4.2±0.12 
2. F2      2.4±0.8 2.43±0.03 4.0±0.20 
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6.5.   In-vitro drug release profile of Formulations 
 
Table. No: 3: Evaluation of Mucoadhesive Tablets 
 
 
S.NO Time (Hrs) Formulations 
F1 F2 
1 0 0 0 
2 0.15 47.5±0.6 16.25±1.5 
3 0.30 62.5±0.4 20.0±0.9 
4 1 88.0±1.2 37.5±1.0 
5 2 - 81.25±0.9 
6 3 - 90.0±1.3 
7 4 - - 
 
 
 6.6. Streptozotocin induced diabetic evaluation 
 
Table. No: 4: Treatment of modified thiozolidine dione tablet against STZ-
induced diabetic rats ( Glucose level mg / dl ) 
 
 
Sl. No Treatment/ Dose 
(mg/ Kg) 
Initial 3
rd
 day 7
th
 day 14
th
 day 
1. Normal Control 
0.5 % CMC 
88.3±3.7 268.3±3.3 288.6±4.3 260.6±6.3 
2. Positive Control 
(Pioglitazone)-2 
87.3±2.9 267.3±3.5 244.8±3.8*** 180.8±4.2 
3. Formulated Drug-
2 
86.7±3.2 268.6±4.8  250±4.7** 185.7±6.8  
 
Values are represented as Mean ± SEM (n=6 rats). Values are statistically significant 
at ** P< 0.01, ***P < 0.001. Diabetic + modified thiozolidinedione compared with 
diabetic + Pioglitazone and normal control rats. 
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Figure. No: 12: Treatment of modified thiozolidine dione tablet against STZ-
induced diabetic rats ( Glucose level mg / dl ) 
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CHAPTER-VI 
7. SUMMARY & CONCLUSION 
 
 
 
The modified thiozolidine dione tablets have anti-diabetic activity, which are 
proved by the help of obtained results. In formulation aspect, mucoadhesive 
formulated modified thiozolidine dione has anti-diabetic activity which may be lesser 
toxicity. As per pharmacological aspect, in future to check toxicity of mucoadhesive 
formulated modified thiozolidine dione if it will be lesser toxicity so elucidate the 
exact structure of the modified thiozolidine dione with help of analytical studies to 
make pattern rights. This works will be useful for upcoming diabetic researchers to 
find new innovative formulation for the treatment of diabetes mellitus, which will be 
lesser adverse effects. 
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